BPC-157: Decades of Animal Work, a Very Thin Human File

The short version

BPC-157 is a synthetic peptide fifteen amino acids long. "Body Protection Compound" comes from its origins as a sequence derived from a protective protein in human stomach juice. In animal studies — overwhelmingly rats — it appears to speed up healing in many tissues: tendons, the gut lining, muscle, and nerve. The explanation researchers give most consistently is that it helps the body grow new blood vessels into an injury, bringing the oxygen and nutrients repair needs ^[4].

Here is the honest part. Almost all of this evidence comes from animals. A 2025 review counted only three small human pilot studies in the entire literature, with no large, rigorous controlled trials ^[2]. BPC-157 is not an approved drug anywhere, it is banned in competitive sport, and popular online claims about weight loss, muscle building, or testosterone are not supported by the published science ^[2]. This page summarizes what was studied; it is not advice and it lists no human dose.

What it is

BPC-157 is a stable gastric pentadecapeptide — fifteen amino acids, derived from a cytoprotective protein in gastric juice, and resistant to breakdown in the stomach. Its amino-acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. You will also see it under research labels such as PL 14736, PLD-116, PL-10, and Bepecin. It is a wholly synthetic research peptide — not a natural extract, not a pharmaceutical product, not an approved drug anywhere.

How it works

The most clearly described mechanism is angiogenesis — the formation of new blood vessels. A 2017 study working across a chick-membrane model, a rat hindlimb ischemia model, and human blood-vessel-lining cells found that BPC-157 increased expression of a key vessel-growth receptor called VEGFR2 and promoted its internalization, activating the downstream VEGFR2-Akt-eNOS pathway; blocking that internalization blocked the effect ^[4]. In plain terms: the peptide appears to make blood-vessel cells more responsive to the body's own "grow new vessels" signal, and it accelerated blood-flow recovery in a blocked-circulation muscle model ^[4].

Researchers also describe BPC-157 as engaging the brain-gut axis — modulating dopamine and serotonin systems and cell-migration pathways (FAK-paxillin), along with sensitizing the growth-hormone receptor in tendon cells. The picture is a peptide that nudges multiple repair-related signals rather than hitting one lock.

What the research shows

Foundational cytoprotection. BPC-157 gets its name partly from its gut origins. In Wistar rats with induced gastric ulcers, it reduced ulcer area and accelerated healing — intramuscular delivery outperforming intragastric — with ulcer-formation inhibition ratios of roughly 46–66% at higher doses ^[5].

Pharmacokinetics. The first formal PK/ADME work in rats and beagle dogs found linear pharmacokinetics, a short elimination half-life under 30 minutes, modest intramuscular bioavailability (about 14–19% in rats, 45–51% in dogs), and rapid breakdown into small fragments that re-enter normal amino-acid metabolism ^[3]. A short half-life means the intact peptide clears the bloodstream quickly after dosing.

Angiogenesis mechanism. The pro-angiogenic story is the most experimentally robust: VEGFR2 up-regulation and internalization drove increased vessel density in multiple models and accelerated blood-flow recovery in a blocked-circulation muscle experiment ^[4].

Human evidence — a very small file. In the first-ever intravenous human safety pilot (2025), BPC-157 up to 20 mg was given to two healthy adults — a 58-year-old man and a 68-year-old woman. It was well tolerated: no adverse events, no measurable changes in cardiac, hepatic, renal, thyroid, or glucose biomarkers ^[1]. Two people does not a safety study make, and the authors were explicit: this was a tolerability pilot, not an efficacy trial.

A 2025 narrative review concluded that only three small human pilot studies exist for BPC-157, that rigorous large-scale trials are lacking, and that the compound should be treated as investigational ^[2].

Reported effects, cautions and safety

The safety picture within the tiny human dataset and the animal work is broadly reassuring — but "as far as it goes" is the phrase that matters, because long-term, large-sample human data simply do not exist yet ^[2].

Several cautions come directly from the literature:

• Evidence is overwhelmingly preclinical. Most findings come from rodents, and a large portion of the foundational work originates from a single research group. Newer reviewers flag this explicitly as raising independent-replication questions ^[2].
• Unregulated supply. BPC-157 is not an approved drug anywhere and circulates through non-regulated channels, so product identity, purity, and dose are unverified outside formal studies.
• Banned in sport. WADA prohibits BPC-157 at all times under the S0 non-approved-substances category — a direct concern for competitive athletes.
• Skeptical claims. Online claims about weight loss, muscle building, or raising testosterone are not supported by the published evidence.

This desk's source material for BPC-157 contains no compiled community-anecdote reports, so none are presented here; all cautions above come from the cited literature.

Where it fits in recovery research

Among the four peptides here, BPC-157 has the broadest animal record — but breadth in animals is not the same as depth in humans. Its preclinical story spans tendon, gut, muscle, and nerve repair, unified by an angiogenesis-forward narrative, while its human file stays at three small pilots ^[2]. Alongside TB-500, which approaches repair through cell migration and actin biology, and GHK-Cu, which has the strongest human topical evidence, BPC-157 illustrates the central tension of this entire field: a coherent, decades-deep preclinical signal that has barely entered controlled human study. See the comparison page for how it lines up against the others.